Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma
To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular
carcinoma
To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma
patients after administration of Oncoxin plus Surafenib
To see if there is reduction tumor size and or number in hepatocellular carcinoma patients
after administration of Oncoxin plus Surafenib
To see if there is improvement of quality of life in hepatocellular carcinoma patients after
administration of Oncoxin plus Surafenib
To see if there is improved survival in hepatocellular carcinoma patients after
administration of Oncoxin plus Surafenib
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of patients who have prolonged survival
To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks
24 weeks
Yes
Mamun A Mahtab, MD, FACG
Principal Investigator
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Bangladesh: Directorate of Drug Administration
OP2
NCT01747642
December 2012
June 2014
Name | Location |
---|